

15750 U.S.PTO
022704

Atty. Dkt. No. 018733-1359

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Shui-on LEUNG et al.
Title: GYLOCOSYLATED HUMANIZED B-CELL
SPECIFIC ANTIBODIES
Prior Appl. No.: 09/894,839
Prior Appl. Filing Date: 06/29/2001
Examiner: Unassigned
Art Unit: 1642

22141 U.S.PTO
10/787378
022704**CONTINUING PATENT APPLICATION
TRANSMITTAL LETTER**

Mail Stop PATENT APPLICATION
Commissioner for Patents
PO Box 1450
Alexandria, Virginia 22313-1450

Sir:

Transmitted herewith for filing under 37 C.F.R. § 1.53(b) is a:

Continuation Division Continuation-In-Part (CIP)

of the above-identified copending prior application in which no patenting, abandonment, or termination of proceedings has occurred. Priority to the above-identified prior application is hereby claimed under 35 U.S.C. § 120 for this continuing application. The entire disclosure of the above-identified prior application is considered as being part of the disclosure of the accompanying continuing application and is hereby incorporated by reference therein.

Enclosed are:

- Application Data Sheet (37 CFR 1.76) (4 pages).
- Specification, Claim(s), and Abstract (51 pages).
- Formal drawings (16 sheets, Figs. 1A-1B, 2A-2B, 3A-3B, 4A-4B, 5A-5B, 6-7, 8A-8B, 9-12)).
- Copy of Declaration and Power of Attorney and Supplemental Declaration and Power of Attorney (8 pages).

Submission of Sequence Listing under 37 C.F.R. §1.821(e) (2 pages).

Copy of Statement to Support Filing and Submission in Accordance with 37 C.F.R. §§1.821-1.825 filed on 10/19/2001 (1 page).

Copy of Sequence Listing filed on 10/19/2001 (19 pages).

The filing fee is calculated below:

	Claims as Filed	Included in Basic Fee	Extra Claims	Rate	Fee Totals
Basic Fee				\$770.00	\$770.00
Total Claims:	15	- 20	= 0	x \$18.00 =	\$0.00
Independents:	1	- 3	= 0	x \$86.00 =	\$0.00
If any Multiple Dependent Claim(s) present:			+ \$290.00 =		\$0.00
			SUBTOTAL: =		\$770.00
[] Small Entity Fees Apply (subtract ½ of above):			=		\$0.00
			TOTAL FILING FEE: =		\$770.00

A check in the amount of \$770.00 to cover the filing fee is enclosed.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Please direct all correspondence to the undersigned attorney or agent at the address indicated below.

Respectfully submitted,

Date Feb. 27, 2004

By Stephen B. Maebius

FOLEY & LARDNER
Customer Number: 22428
Telephone: (202) 672-5569
Facsimile: (202) 672-5399

Stephen B. Maebius
Attorney for Applicants
Registration No. 35,264

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket No: 018733/1049

In re patent application of

LEUNG, Shui-on *et al.*

Serial No.: 09/894,839

Group Art Unit: 1642

Filed: June 29, 2001

Examiner: Unknown

For: GLYCOSYLATED HUMANIZED B-CELL SPECIFIC ANTIBODIES

**STATEMENT TO SUPPORT FILING AND SUBMISSION IN
ACCORDANCE WITH 37 C.F.R. §§ 1.821-1.825**

Commissioner for Patents
Washington, D.C. 20231
Box SEQUENCE

Sir:

In connection with a Sequence Listing submitted concurrently herewith, the undersigned hereby states that:

1. the submission, filed herewith in accordance with 37 C.F.R. § 1.821(g), does not include new matter; and

2. the content of the attached paper copy and the attached computer readable copy of the Sequence Listing, submitted in accordance with 37 C.F.R. § 1.821(c) and (e), respectively, are the same.

Respectfully submitted,

October 19, 2001
Date


Bernhard D. Saxe
Reg. No. 28,665

FOLEY & LARDNER
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5109
Telephone: (202) 672-5300
Facsimile: (202) 672-5399

BEST AVAILABLE COPY